Skip to content

US · EDSA · BIOTECHNOLOGY

Edesa Biotech, Inc. (EDSA) intrinsic value and stock valuation

$2.00as of 2026-11-21 · Mkt cap 49.8M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Edesa Biotech, Inc. DCF and intrinsic value

InvestorsCraft values EDSA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EDSA’s statements →

Edesa Biotech, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Markham, ON L3R 5H6 edesabiotech.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-7.19M
20112025
Free cash flow
-$-7.32M
20112025
Total equity
$12.5M+13.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-7.91M-$-7.01M-$-9.22M-$-18.37M-$-23.68M
Net income-$-7.19M-$-6.17M-$-8.37M-$-17.55M-$-13.34M
EPSd-$-1.27M-$-1.93M-$-2.93M-$-8.36M-$-7.71M
Operating cash flow-$-7.32M-$-4.89M-$-6.64M-$-12.28M-$-13.66M
Capital expenditure$0.00$0.00$0.00-$-10K-$-10K
Free cash flow-$-7.32M-$-4.89M-$-6.64M-$-12.28M-$-13.67M
Total assets$13.5M$3.81M$8.89M$11.6M$14.6M
Total debt$0.00$20K$90K$20K$100K
Net debt-$-10.79M-$-1.02M-$-5.27M-$-7.07M-$-7.74M
Total equity$12.5M$1.98M$7.05M$9.39M$13.1M
Cash and short-term investments$10.8M$1.04M$5.36M$7.09M$7.84M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$120K$190K$180K$120K$120K
Gross profit-$-120K-$-190K-$-180K-$-120K-$-120K
Research and development expenses$3.67M$2.88M$4.79M$13.3M$18M
Selling, general and administrative expenses$4.24M$4.13M$4.43M$5.04M$5.73M
Other expenses-$-120K$0.00$0.00$0.00$0.00
Operating expenses$7.79M$7.01M$9.22M$18.4M$23.7M
Cost and expenses$7.91M$7.01M$9.22M$18.4M$23.7M
Interest income$0.00$150K$290K$0.00$10K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$120K$190K$180K$120K$120K
Ebitda-$-7.07M-$-5.98M-$-8.19M-$-17.43M-$-13.22M
Operating income-$-7.91M-$-7.01M-$-9.22M-$-18.37M-$-23.68M
Total other income/expenses, net$730K$850K$850K$820K$10.3M
Income before tax-$-7.18M-$-6.17M-$-8.37M-$-17.55M-$-13.34M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-7.19M-$-6.17M-$-8.37M-$-17.55M-$-13.34M
Weighted average shares outstanding$5.68M$3.2M$2.86M$2.1M$1.73M
Weighted average diluted shares outstanding$5.68M$3.2M$2.86M$2.1M$1.73M
Balance sheet
20252024202320222021
Cash and short-term investments$10.8M$1.04M$5.36M$7.09M$7.84M
Net receivables$640K$270K$630K$1.26M$3.3M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$11.5M$1.68M$6.44M$9.09M$12.1M
Property, plant and equipment, net$0.00$20K$100K$30K$110K
Goodwill and intangible assets$1.98M$2.08M$2.18M$2.28M$2.38M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.02M$2.14M$2.45M$2.48M$2.49M
Total assets$13.5M$3.81M$8.89M$11.6M$14.6M
Accounts payable$0.00$1.81M$1.75M$2.12M$1.38M
Short-term debt$0.00$20K$70K$20K$80K
Deferred revenue$0.00$0.00$0.00-$-2.12M$0.00
Total current liabilities$1.08M$1.83M$1.82M$2.14M$1.46M
Long-term debt$0.00$0.00$20K$0.00$20K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$130K$20K$40K$70K
Capital lease obligations$0.00$20K$90K$20K$100K
Total liabilities$1.08M$1.83M$1.84M$2.18M$1.53M
Common stock$54.5M$47.2M$46.6M$42.5M$34.9M
Retained earnings-$-65.91M-$-58.59M-$-52.42M-$-44.04M-$-26.5M
Accumulated other comprehensive income (loss)-$-170K-$-240K-$-210K-$-210K-$-210K
Total equity$12.5M$1.98M$7.05M$9.39M$13.1M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$20K$90K$20K$100K
Net debt-$-10.79M-$-1.02M-$-5.27M-$-7.07M-$-7.74M
Cash flow statement
20252024202320222021
Net income-$-7.19M-$-6.17M-$-8.37M-$-17.55M-$-13.34M
Depreciation and amortization$120K$190K$180K$120K$120K
Stock-based compensation$730K$540K$1.25M$2.26M$3.2M
Change in working capital-$-990K$570K$310K$2.89M-$-3.64M
Accounts receivable-$-380K$360K$560K$2.03B-$-3.23M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00-$-560K$880K-$-120K
Net cash provided by operating activities-$-7.32M-$-4.89M-$-6.64M-$-12.28M-$-13.66M
Investments in property, plant and equipment$0.00$0.00$0.00-$-10K-$-10K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00-$-10K-$-10K
Common stock issued$17M$620K$4.83M$11.6M$14.2M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$17M$590K$4.83M$11.6M$14.2M
Net change in cash$9.75M-$-4.32M-$-1.73M-$-750K$630K
Cash at end of period$10.8M$1.04M$5.36M$7.09M$7.84M
Operating cash flow-$-7.32M-$-4.89M-$-6.64M-$-12.28M-$-13.66M
Capital expenditure$0.00$0.00$0.00-$-10K-$-10K
Free cash flow-$-7.32M-$-4.89M-$-6.64M-$-12.28M-$-13.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Edesa Biotech, Inc.

        Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

        CEO
        Pardeep Nijhawan
        Employees
        17
        Beta
        1.05

        Explore

        Frequently asked questions

        What is the intrinsic value of Edesa Biotech, Inc. (EDSA)?

        InvestorsCraft does not currently publish an intrinsic value for EDSA. How the IC value is calculated.

        Is EDSA undervalued?

        InvestorsCraft does not publish an undervaluation signal for EDSA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.